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Guillain-Barré syndrome (GBS) is an acute
demyelinating polyneuropathy characterized by
an immunologic attack upon peripheral nerve
myelin (1,2). The trigger for this immune attack
is unknown; however, GBS is frequently preceded
by an acute infectious illness (3). In recent years,
infection with Campylobacter jejuni has emerged as
one of the most common antecedent events
associated with GBS. Up to 40% of patients with
GBS have culture or serologic evidence of C. jejuni
infection when neurologic symptoms begin (4-6).
The many variants of GBS—including acute motor
axonal neuropathy, acute inflammatory demyeli-
nating neuropathy, and Miller Fisher syndrome—
have also been associated with preceding C. jejuni
infection (7-9).
C. jejuni infections are common in the United
States, affecting approximately 1% of the
population each year (10). Typically, they cause a
self-limited gastrointestinal illness characterized
by diarrhea, abdominal pain, and fever. However,
approximately 1 in 2,000 C. jejuni infections may
be complicated by GBS (11).  Because C. jejuni
infections occur far more commonly than GBS,
either host (12) or strain (5,13) characteristics
may determine which infected persons contract
GBS. Several reports from Japan showed that a
particular serotype, O:19, was overrepresented
among  C. jejuni strains isolated from GBS
patients (5,13). Among 12 Japanese patients with
GBS and culture-confirmed C. jejuni infection, 10
(83%) were infected with strains of O:19, a
serotype that accounts for only 2% of randomly
selected C. jejuni isolates in Japan (5). However,
in England, none of four C. jejuni strains isolated
from patients with GBS were serotype O:19 (6).
Other  Campylobacter serotypes predominate
among GBS patients in other parts of the world.
All nine C. jejuni strains isolated from GBS
patients in South Africa were serotype O:41 (14);
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Guillain-Barré syndrome (GBS), an acute demyelinating peripheral neuropathy, may
be triggered by an acute infectious illness; infection with Campylobacter jejuni is the most
frequently reported antecedent event. In Japan, O:19 is the most common serotype
among GBS-associated C. jejuni strains. To determine whether serotype O:19 occurs
among GBS-associated strains in the United States and Europe, we serotyped seven
such strains and found that two (29%) of seven GBS-associated strains from patients in
the United States and Germany were serotype O:19.  To determine whether GBS-
associated strains may be resistant to killing by normal human serum (NHS), we studied
the serum susceptibility of 17 GBS- and 27 enteritis-associated strains (including many
O:19 and non-O:19 strains) using C. jejuni  antibody positive (pool 1) or negative (pool 2)
human serum. Using pool 1 serum we  found that one (6%) of 18 serotype O:19 strains
compared with 11 (42%) of 26 non-O:19 strains were killed; results using pool 2 serum
were nearly identical. Finally, 8 O:19 and 8 non-O:19 strains were not significantly different
in their ability to bind complement component C3. Serotype O:19 C. jejuni strains were
overrepresented among GBS-associated strains in the United States and Germany and
were significantly more serum-resistant than non-O:19 strains. The mechanism of this
resistance appears unrelated to C3 binding.264 Emerging Infectious Diseases Vol. 4, No. 2, April–June 1998
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this serotype accounts for fewer than 2% of
isolates from South African children with
uncomplicated enteritis. With Lior typing (a
serotyping system based upon heat-labile
antigens), all four GBS-associated C. jejuni
strains in Germany were serotype O:11 (15).
Whether the predominance of O:19 strains
among GBS patients is limited to Japan is not
clear. Furthermore, the reason for the O:19
overrepresentation among Japanese GBS strains
is unknown, but their resistance to host bacterial
clearance mechanisms is one possibility. C. jejuni
strains vary in their susceptibility to the
bactericidal activity in normal human serum (NHS)
(16). Bacteria that are more resistant to nonspecific
serum killing may elicit more extensive specific
responses to eliminate the organism; such elicited
immune responses may have the potential of
greater tissue injury and myelin damage.
To determine whether C. jejuni serotype O:19
is an important cause of GBS outside Japan, we
serotyped GBS-associated strains from the United
States and Germany. To investigate the immuno-
logic response to GBS-associated C. jejuni strains,
we performed two additional sets of experiments.
First, we examined the susceptibility of C. jejuni
strains to NHS. Our hypothesis was that GBS-
associated  Campylobacter strains, more specifically
O:19 strains, are more serum-resistant than those
from patients with uncomplicated enteritis. To
further characterize the mechanism of resistance,
we determined whether C. jejuni strains isolated
from GBS patients differ in their capacity to bind
complement component C3.
Statistical Analysis
 We determined mean values, standard devia-
tions, odds ratios, p-values, paired T-tests, 95%
confidence limits, and interquartile ranges. Software
included Lotus 123 and EpiInfo (a statistical software
package designed by the Centers for Disease Control
and Prevention [CDC]).
Serotyping of Strains
Seven GBS-associated strains were serotyped
with the O (formerly heat-stable) serotyping
scheme of Penner and Hennessy (17) and the
heat-labile serotyping scheme of Lior (18).
Serotyping was conducted (19) at the CDC
Campylobacter Reference Laboratory. A GBS-
associated strain was defined as one isolated from
a patient with GBS (n = 6) or from a patient
infected during an outbreak in which at least one
infected person contracted GBS (n = 1). Four
strains were from patients in the United States,
and three were from patients in Germany; four of
these were isolated from women.
Serotype O:19 was present in one of four U.S.
GBS-associated C. jejuni isolates and one of three
German isolates. Thus, 2 (29%) of 7 GBS-
associated  C. jejuni isolates from patients in the
United States and Germany were O:19. The O
and heat-labile serotypes of the seven GBS-
associated strains are shown in Table 1.
Serum Bactericidal Assays
We studied 44 GBS- and enteritis-associated
strains from all over the world. We divided C.
jejuni isolates into two major groups. Group 1 (17
GBS-associated strains) was divided into two
subgroups. Subgroup 1A (GBS-associated/type
O:19) consisted of seven C. jejuni O:19 isolates:
three from the United States, three from Japan,
and one from Germany. Subgroup 1B (GBS-
associated/non-O:19 serotype) consisted of 10 C.
jejuni isolates with serotypes other than O:19:
three from the United States, two from Germany,
and five from England. Group 2 (27 enteritis-
associated strains from patients with uncompli-
cated enteritis but no known GBS association)
was also divided into two subgroups. Subgroup
2A (not GBS-associated/type O:19) consisted of 11
C. jejuni O:19 isolates: 10 from the United States
and one from Japan. Subgroup 2B (not GBS-
associated/non-O:19 serotype) consisted of 16 C.
jejuni isolates from U.S. patients with serotypes
other than O:19. Serum-resistant C. fetus strain
23D and its spontaneous serum-susceptible
mutant, 23B, were used as controls (20).
Strains were grown on trypticase soy blood
agar plates (BBL Cockeysville, MD, USA) at 37oC
for 48 hours in an incubator containing 10% CO2,
5% O2, and 85% N2. The bacteria were harvested
in 0.15M saline and centrifuged at 8,000 g for 15
minutes. The supernatant was discarded, the
pellet was resuspended in 300 µl of saline, and 10-
fold serial dilutions were performed in saline.
From the 10-4, 10-5, and 10-6 dilutions, 400 µl
aliquots of cells were added to 1.2 ml of Hanks
balanced salt solution (HBSS).
Two sources of NHS were used in these
assays. Pool 1 consisted of serum from five
healthy adults that was pooled, aliquotted, and
frozen at -70°C. The level of C. jejuni antibodies in
pool 1 serum was determined by enzyme-linked
immunosorbent assay (ELISA) (4). The optical265 Vol. 4, No. 2, April–June 1998 Emerging Infectious Diseases
Perspectives
density ratio (ODR) for immunoglobulin G (IgG)
was 5.14; the ODR for IgM was 0.66.
Documentation of previous C. jejuni infection
was not required to be included in this pool. In
contrast, pool 2 consisted of serum from two
healthy adults with only low-titer antibody. The
ODR for pool 2 serum in the IgG assay was 0.37;
and the ODR in the IgM assay was 0.30. As a
control, the NHS was heated to 56oC for 30
minutes (heat inactivated NHS [HINHS]) to
ablate all complement activity.
The assay to determine susceptibility to NHS
was performed in sterile, disposable 96-well
microtiter U-bottom plates (Falcon MICROTEST
III, Becton Dickinson & Co., Franklin Lakes, NJ,
USA). From each of the bacterial suspensions, a
150 µl aliquot was added to duplicate wells. In
addition, 50 µl of NHS or HINHS (diluted to 40%
with HBSS) was added; the final serum
concentration in the suspension was 10%. After
the assay plate was incubated at 37oC for 1 hour,
50 µl of the suspension from each well was poured
onto blood agar plates and incubated for 48 hours;
the number of CFUs was then calculated. The
difference between the counts for cells incubated
with NHS and HINHS was expressed as median
log10 kill for each strain; greater than 1 log10 kill was
considered a serum-susceptible strain (21). If less
than 1 log10 kill occurred, the strain was considered
serum-resistant. The identical procedure was
performed using pool 1 and pool 2 serum.
The resistance of the 44 C. jejuni strains
studied to killing by NHS is shown in Table 2. Of
these strains, 12 (27%) were resistant to killing
by C. jejuni antibody-positive pool 1 serum and 10
(23%) were resistant to killing by C. jejuni
antibody-negative pool 2 serum; thus, as
described previously (22), antibodies to C. jejuni
had little impact on serum-killing. The GBS-
associated strains were no more likely to be
resistant to serum-killing than were the strains
from patients with uncomplicated enteritis.
However, O:19 strains were significantly more
likely than other C. jejuni serotypes to resist
serum-killing, regardless of GBS-association and
serum pool used (Table 2). In serum pool 1, only 1
of 18 O:19 strains was serum-susceptible
compared with 11 (42%) of 26 non-O:19 strains
(odds ratio = 12.5, p = 0.008). Similarly, in serum
pool 2, no O:19 strain was serum-susceptible
compared with 10 (38%) of the non-O:19 isolates.
125I-C3 Binding Assays
Eight strains from Group 1 (four randomly
selected from each subgroup) and eight from
Group 2 (four randomly selected from each
subgroup) were grown on blood agar plates as
described above. C. fetus strains 23D and 23B
again served as controls and the assays were
conducted (21). In brief, bacteria from each plate
were harvested in 1.5 ml of HBSS and were
centrifuged at 8,000 g for 15 minutes; the pellet was
resuspended in 0.5 ml HBSS and adjusted to OD450
= 3.0. For each strain studied, a suspension of 4 µl
125I-C3 (with 20,000 cpm to 65,000 cpm) and 2.5 µl of
either NHS or HINHS from pool 2 and 100 µl of the
bacteria-HBSS suspension were incubated at 37oC
for 15 minutes. 125I-C3 was prepared in the
laboratory of one of the authors (RGW) (21). The
suspensions were then centrifuged twice at 175xg
for 5 minutes, the pellet was resuspended in HBSS,
and the supernatant was discarded. The bottom 5
mm (containing the pellet) of each tube was clipped,
and emissions were determined in a gamma
counter. The counts in the negative control
mixtures containing HINHS were subtracted from
the NHS counts. An assay was considered valid
only if the net pellet counts (NHS minus HINHS)
for control strain 23B were at least four times
higher than for 23D. To control for nonspecific
binding, the counts for each strain studied were
expressed as the ratio of net counts relative to the
serum susceptible control (23B). Each strain was
assayed two to four times.
Mean binding of serum-susceptible control
strain 23B was 497 cpm, whereas mean binding of
serum-resistant control strain 23D was 54. The
Table 1. Serotypes of Guillain-Barré syndrome–
associated  Campylobacter jejuni strains from the United
States and Germany
(O)a- (HL)b
 Strain designation sero- sero- Age/
CDCc Vanderbiltd type type Location sex
D459 93-002 19 77 Florida 79F
D2769 93-006   2   4 Maine F
D4262 84-158 19 84 Germany 59F
D4266 84-196   2   4 Germany 24M
D4267 84-197   8,17 40 Germany 71F
D4271 86-381   2   4 Wisconsin 30M
D4808 93-001   1   4 Washington 57M
aO = heat-stable.
bHL = heat-labile.
cDesignated strain number assigned by the Centers for
Disease Control and Prevention Campylobacter Reference
Laboratory.
dDesignated strain number in the Vanderbilt Campy-
lobacter/Helicobacter strain collection.266 Emerging Infectious Diseases Vol. 4, No. 2, April–June 1998
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mean ratio of C3-binding for strain 23D to 23B of
0.114 was as expected (21). In contrast, the mean
ratio for C3 binding to C. jejuni strains in
comparison with strain 23B was 0.022 to 0.464
(mean 0.216). The eight O:19 strains were not
significantly different from the eight non-O:19
strains in their ability to bind 125I-C3 (Table 3).
Conclusion
This study of GBS patients in the United
States and Germany confirms the observation
made in Japan that serotype O:19 is overrepre-
sented among patients with C. jejuni-induced
GBS. Of 298 randomly collected Campylobacter
isolates from patients with enteritis in the United
States, only 3% were serotype O:19 (19). A
similarly low prevalence of O:19 strains is found
in all parts of the world, including North and
South America, Asia, and Europe (5,6,19,23).
Although specific serotyping surveys have not
been done in Germany, it is unlikely that
serotype O:19 is more frequent among German C.
jejuni isolates. Thus, the GBS-associated strains
in our study were more than 11 times as likely to
belong to this serotype (p = 0.03). Although the
association among GBS and C. jejuni serotype
O:19 was not as marked as in Japan (where more
than 80% of GBS-associated isolates are O:19),
this serotype clearly is overrepresented among
GBS-associated strains in other countries. We
conclude that the association of O:19 strains with
GBS is not just a local phenomenon in Japan but
likely reflects a fundamental characteristic of
O:19 strains. O-serotype 2 and heat-labile
serotype 4, which were common among the GBS
strains, are commonly represented among
infected persons in the United States (23).
Despite the frequency of Campylobacter
infections in GBS patients, such strains are
difficult to obtain for several reasons. First, in
most C. jejuni-infected patients, stools are clear
before neurologic symptoms begin. Second, most
neurologists do not culture stool samples when
GBS is first diagnosed. And finally, even if a stool
culture is ordered and Campylobacter is present,
few microbiology laboratories save their isolates;
by the time the case is reported, the strain has
been discarded. Thus, these seven strains
represent one of the largest collections of GBS-
associated strains described. Additionally, these
are likely to be representative of the population of
GBS-associated C. jejuni strains. Unless serotype
O:19 strains persist in stools longer, are more
easily cultured, or are less likely to be discarded
by microbiology laboratories (and no data support
any of these possibilities), these strains probably
are not different in any systematic way from
other GBS-associated isolates.
Most  C. jejuni strains are susceptible to
killing by human serum (22), but because we
studied highly selected strains (most either
serotype O:19 or from GBS patients), a high
proportion of strains in this investigation were
resistant. In this context, the finding that C.
jejuni strains from GBS patients were no more
likely than the strains from patients with
uncomplicated enteritis to be serum resistant is
not surprising. Even when the analysis was
limited only to serotype O:19 strains, no
differences were found between GBS- and
enteritis-associated strains. However, serotype
O:19 strains were substantially less serum-
Table 2. Susceptibility of Campylobacter jejuni strains to killing by normal human serum (NHS)
No. of No. (%)  with Median log kill
O strains  >1 log killa,b (interquartile range)
Illness serotype studied Pool 1c Pool 2c Pool 1 Pool 2
GBSd 19   7   1 (14)   0  (0) 0.53 (0.18-0.63) 0.39 (0.08-0.52)
Enteritis 19 11   0  (0)   0  (0) 0.37 (0.09-0.47) 0.48 (0.29-0.50)
GBS non-19 10   3 (30)   3 (30) 0.70 (0.44-1.18) 0.43 (0.03-1.32)
Enteritis non-19 16   8 (50)   7 (44) 0.90 (0.24-2.00) 0.59 (0.35-2.53)
All 19 18   1 (6)   0 (0) 0.38 (0.17-0.58) 0.45 (0.23-0.52)
All non-19 26 11 (42) 10 (38) 0.70 (0.26-1.86) 0.54 (0.17-2.27)
aBacterial suspensions were incubated in either NHS or heat inactivated NHS at 37°C for 1 hr as described in text, and net
CFU (NHS minus HINHS) determined.  Values greater than 1 log10 kill were considered to denote a serum-susceptible strain.
bComparison of O:19 strains with non-O:19 strains:  Pool 1, odds ratio = 12.5, p = 0.008;  Pool 2, odds ratio = undefined, p =
0.003.
cPool 1 consists of C. jejuni-antibody positive serum from five healthy adults; Pool 2 consists of C. jejuni-antibody negative
serum from two healthy adults.
dGBS = Guillain-Barré syndrome.267 Vol. 4, No. 2, April–June 1998 Emerging Infectious Diseases
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susceptible than strains of other serotypes and
were 12 times as likely to be serum-resistant.
Although serotype O:19 represents only a small
percentage of C. jejuni strains from patients with
uncomplicated enteritis in the United States or
Japan, it is the most common serotype identified
in GBS patients in both locales. The relatively
small variation in serum susceptibility of the
O:19 strains is consistent with the close genetic
relationship observed among these strains (24).
To better understand the basis for the
relative serum-resistance among the O:19
strains, we compared their ability to bind C3 in
relation to non-O:19 strains. Because C3 binding
occurs after activation by either the alternative
or classical complement pathways, it is a screen
for differences in these early steps. The serum-
resistance of C. fetus is explained by the inability
of C3 to bind to the cell surface (25). In contrast,
C3 binding is normal in serum-resistant
Salmonella, but the C5-9 membrane attack
complex does not insert properly (26). In the
present study, the lack of substantial C3 binding
differences among O:19 and non-O:19 C. jejuni
strains suggests that the early steps in
complement activation are similar among
strains. However, clear differences in serum-
susceptibility bespeak either rapid inactivation
of C3 or reduced assembly or function of the
membrane attack complex in the more resistant
strains. Future studies should address this point.
The increasing awareness of the importance
of C. jejuni infection in triggering GBS is another
example of how previously well-described
diseases have emerged as sequelae of acute
infectious illnesses. This study attempts to begin
to characterize the nature of this association;
however, there is much to learn about how an
acute gastrointestinal infection results in
ascending paralysis. One fact is quite clear: many
more people are infected with C. jejuni than
contract GBS subsequently. Perhaps some
persons are predisposed to contracting GBS after
infection with campylobacters that might cause
only uncomplicated enteritis in another patient.
Conversely, as we have suggested in this paper,
some strains may be more likely than others to
trigger GBS. No associations between human
leukocyte antigen (HLA) types and GBS have
been found (27,28). However, in Great Britain
and Japan, an association between HLA type and
C. jejuni-associated GBS has been suggested
(9,29). Perhaps some combination of familial
susceptibility, HLA type, strain serotype, or other
host or strain characteristics together play a role
in the pathogenesis of C. jejuni-induced GBS.
The relative serum-resistance of O:19 strains
correlates with mechanism. Furthermore, the
relevance of these in vitro assays to the
susceptibility of organisms in vivo cannot be
known with certainty. We speculate that the
relative insensitivity of these strains to the lytic
effects of complement allows them to trigger a
heightened specific immunologic response. We
further speculate that this heightened immuno-
logic response leads to injury of peripheral nerve
structures. Since only a small fraction of
infections caused by C. jejuni O:19 lead to GBS
(estimated incidence 1 in 158) (30), additional
factors also must be involved in vivo.
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Table 3. Comparison of 125I-C3 binding to Campy-
lobacter jejuni strains
Measure Serotype of C. jejuni strain
  O:19 non-O:19
(n = 8)  (n = 8)
Counts per minutea 85 +/-51 98 +/- 48
Mean binding ratiob 0.187 +/- 0.245 +/-
  0.116   0.130
aBacterial cells were incubated with pool 2 normal human
serum or heat inactivated normal human serum and 125I-C3
(mean 40,416 [range 20,234-63,503]. cpm) at 37oC for 15
minutes.  The cells were centrifuged and washed; net (NHS
minus HINHS) 125I binding was measured as counts per
minute. p-value = 0.20 (paired T-test, 1-tailed).
bThe mean binding ratio is an average of the ratio of the net
counts for each study strain relative to the net counts of the
serum-susceptible control (23B). p-value = 0.31 (paired T-
test, 1-tailed).268 Emerging Infectious Diseases Vol. 4, No. 2, April–June 1998
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